COGNITION THERAPEUTICS

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

22 Apr 2024 07:30:22 By Nasdaq GlobeNewswire

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

02 Apr 2024 07:30:47 By Nasdaq GlobeNewswire

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024

01 Apr 2024 07:30:39 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

26 Mar 2024 07:00:56 By Nasdaq GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

15 Mar 2024 07:30:59 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock

14 Mar 2024 16:05:15 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock

11 Mar 2024 20:16:05 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Proposed Public Offering of Common Stock

11 Mar 2024 16:05:16 By Nasdaq GlobeNewswire

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

06 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Present at the TD Cowen Health Care Conference

26 Feb 2024 07:30:59 By Nasdaq GlobeNewswire

New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

06 Feb 2024 08:47:22 By Nasdaq GlobeNewswire

Cognition Therapeutics CEO Issues Letter to Shareholders

04 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens

16 Nov 2023 07:30:35 By Nasdaq GlobeNewswire

Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases

15 Nov 2023 07:30:48 By Nasdaq GlobeNewswire

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

07 Nov 2023 07:30:25 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

02 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD

27 Oct 2023 07:30:15 By Nasdaq GlobeNewswire

Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD

24 Oct 2023 16:30:41 By Nasdaq GlobeNewswire

Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications

16 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD

07 Sep 2023 07:45:45 By Nasdaq GlobeNewswire